NL-103

• Target:

  HDAC|||Hedgehog/Smoothened|||Others

• Related Pathways:

  Others|||GPCR/G Protein|||Stem Cells|||Chromatin/Epigenetic|||DNA Damage/DNA Repair

• Bioactivity:

  NL-103 is a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. NL-103 comprises structural elements of Hh pathway inhibitor vismodegib, and histone deacetylase (HDAC) inhibitor vorinostat. NL-103 simultaneously and significantly inhibited both HDACs and Hh pathway. Importantly, NL-103 effectively overcame vismodegib resistance induced by Smoothened point mutations. Moreover, NL-103 significantly downregulated the expression of Gli2 which plays an important role in Hh pathway. NL-103 may be a promising compound for clinical development as a more effective Hh pathway inhibitor.

• Smiles:

  N (C (=O) C1=CC (Cl) =CC=C1) C2=CC (NC (=O) C=3C=CC (NCCCCCCC (NO) =O) =NC3) =CC=C2Cl

• Molecular Formula:

  C26H27Cl2N5O4

• Molecular Weight:

  544.43

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1788896-33-2